Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceutica...
FDA Drug Recall #D-0641-2020 — Class II — December 17, 2019
Recall Summary
| Recall Number | D-0641-2020 |
| Classification | Class II — Moderate risk |
| Date Initiated | December 17, 2019 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Glenmark Pharmaceuticals Inc., USA |
| Location | Mahwah, NJ |
| Product Type | Drugs |
| Quantity | 98,988 bottles |
Product Description
Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30
Reason for Recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution Pattern
Natiowide
Lot / Code Information
7701429A 7701522A 7702255A 7704745A 19190456 19190472 19190490
Other Recalls from Glenmark Pharmaceuticals Inc., USA
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0246-2026 | Class II | Ondansetron Orally Disintegrating Tablets, USP,... | Dec 30, 2025 |
| D-0199-2026 | Class III | Bisoprolol Fumarate and Hydrochlorothiazide Tab... | Nov 21, 2025 |
| D-0222-2026 | Class III | Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... | Nov 18, 2025 |
| D-0662-2025 | Class II | Azelaic Acid Gel, 15%, 50 grams, For Topical Us... | Sep 17, 2025 |
| D-0021-2026 | Class II | Viorele, Desogestrel and Ethinyl Estradiol, USP... | Sep 3, 2025 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.